Nyxoah Strengthens its Executive Leadership Team
28 November 2023 - 10:30PM
Nyxoah Strengthens its Executive Leadership Team
Nyxoah Strengthens its Executive
Leadership TeamFrancis Kim appointed as Chief Regulatory
and Quality Officer
Mont-Saint-Guibert, Belgium – November
28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), today announced the appointment of Francis Kim
as Chief Regulatory and Quality Officer. Francis will be leading
Nyxoah’s Global Regulatory and Quality departments.
Francis is a highly experienced global
regulatory and quality executive in the healthcare industry, having
spent more than 25 years in the medical device and life sciences
sector. Francis has led Regulatory and Quality departments at
Medtronic, Philips, and other companies, including introducing
several innovative products and therapies to the market.
“Nyxoah is entering the most exciting time in
the Company’s history, with data from the DREAM U.S. pivotal study
in early 2024, followed by submission of the final module in our
modular PMA and FDA approval expected by the end of the year. I am
excited having someone with Francis’ regulatory and quality
experience joining Nyxoah at this important time, and I look
forward to continued investments as we prepare to for a U.S. market
entrance,” commented Olivier Taelman, Nyxoah Chief Executive
Officer.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors’ therapy. Additionally,
the Company is currently conducting the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contacts:NyxoahDavid DeMartino,
Chief Strategy Officerdavid.demartino@nyxoah.com+1 310 310 1313
- ENGLISH_Nyxoah Strengthens its Executive Leadership Team
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Sep 2023 bis Sep 2024